Latest Content

Explore the complexities of personality disorders in correctional settings and discover effective treatment strategies for better mental health outcomes.

Emergency departments face challenges in detecting suicidality among trauma patients, highlighting the need for effective screening and intervention strategies.

Explore the evolving language of mental health as it intersects with societal issues, highlighting the importance of the term "upstander" in psychiatry.

Explore the intersection of cultural trauma and mental health, emphasizing the importance of awareness and education in preventing future conflicts.

A clinical trial reveals challenges in assessing schizophrenia symptoms due to cultural and language differences, highlighting the need for improved measurement tools.

Psychiatric Times is excited to embrace change with new digital editions and engaging content, and invite you, our readers, to explore diverse topics across multiple platforms.

Reviva Pharmaceuticals reveals promising clinical trial data on brilaroxazine, highlighting its potential to treat negative symptoms in schizophrenia.

Explore the complex relationship between epilepsy and psychosis, including forced normalization and treatment strategies for affected patients.

Athletes navigate stress as a performance factor, learning to harness it for optimal results through effective management strategies and support systems.

Psychiatric Times embraces innovation with interactive digital issues and a new print format, enhancing accessibility for psychiatric clinicians.

Acceptance paves the way for a critical trial of COMP360, a synthetic psilocybin that has the potential to transform PTSD care.

The FDA has granted Breakthrough Therapy designation to Alkermes' alixorexton for narcolepsy type 1, which could offer hope for improved wakefulness and reduced daytime sleepiness.

Cognition Therapeutics shares zervimesine's promising phase 2 results, showing safety and improved symptoms in dementia with Lewy bodies.